[Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2018 Sep 12

PMID 30201068

Citations 5

Authors

Xin Wang

Diansheng Zhong

Affiliations

Soon will be listed here.

Abstract

Molecular target therapy is one of the most popular field of non-small cell lung cancer (NSCLC) treatmnet. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearragement are the most important two oncogenic drivers in NSCLC, early studies suggested that EGFR mutations and ALK rearrangements are mutually exclusive, but isolated cases or small sample research with concomitant EGFR and ALK alterations have been constantly reported. The co-occurrence of EGFR mutations and anaplastic lymphoma kinase (ALK) rearrangements constitutes a rare molecular, the frequency of EGFR/ALK co-alterations was about 1%, however, little has been known about clinicopathologic feature and treatment. This review summarized published case report, EGFR and ALK alterations are common in female, Asian origin, never smoker, IV stage, and denocarcinomas. First-line treatment can choose EGFR or ALK tyrosine kinase inhibitors (TKIs). However, studies about the origin and resistance mechanism in EGFR/ALK co-alterations are little, require more experimental and clinical research. .

Citing Articles

Concomitant ALK Fusion and TP53/EGFR Mutation Lead to Adverse Prognostic Outcome.

Du M, Liu C, Chen L, Li Z, Zhang S, Meng R Clin Respir J. 2024; 18(12):e70041.

PMID: 39681089 PMC: 11649250. DOI: 10.1111/crj.70041.

[Non-small Cell Lung Cancer with Metachronous Mutations of EGFR and ALK Genes:  A Case Report and Literature Review].

Kong X, Wang M, Tang Q, Sun M, Hu J Zhongguo Fei Ai Za Zhi. 2024; 27(7):559-564.

PMID: 39147711 PMC: 11331256. DOI: 10.3779/j.issn.1009-3419.2024.106.15.

Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study.

Zhong W, Wei X World J Clin Cases. 2022; 10(33):12164-12174.

PMID: 36483819 PMC: 9724548. DOI: 10.12998/wjcc.v10.i33.12164.

EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report.

Lu Z, Wang X, Luo Y, Wei J, Zeng Z, Xiong Q Onco Targets Ther. 2021; 14:2823-2828.

PMID: 33935502 PMC: 8079359. DOI: 10.2147/OTT.S294635.

[Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI].

Shao Y, Zhong D Zhongguo Fei Ai Za Zhi. 2020; 23(5):381-387.

PMID: 32429639 PMC: 7260378. DOI: 10.3779/j.issn.1009-3419.2020.101.04.

References

Zhao N, Zheng S, Yang J, Zhang X, Xie Z, Xie B . Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review. Clin Lung Cancer. 2014; 16(2):e5-9. DOI: 10.1016/j.cllc.2014.11.001. View

Zhou J, Zheng J, Zhao J, Sheng Y, Ding W, Zhou J . Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement. Thorac Cancer. 2015; 6(2):216-9. PMC: 4448493. DOI: 10.1111/1759-7714.12146. View

Lee J, Kim T, Koh Y, Lee S, Kim D, Jeon Y . Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer. 2012; 77(2):460-3. DOI: 10.1016/j.lungcan.2012.04.012. View

Caliez J, Monnet I, Pujals A, Rousseau-Bussac G, Jabot L, Boudjemaa A . [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement]. Rev Mal Respir. 2016; 34(5):576-580. DOI: 10.1016/j.rmr.2016.08.002. View

Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L . Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. Clin Lung Cancer. 2015; 17(5):384-390. DOI: 10.1016/j.cllc.2015.11.004. View

Cai W, Lin D, Wu C, Li X, Zhao C, Zheng L . Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. J Clin Oncol. 2015; 33(32):3701-9. PMC: 4770798. DOI: 10.1200/JCO.2014.58.8293. View

Thumallapally N, Yu H, Farhan M, Ibrahim U, Odiami M . Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature. J Pharm Pract. 2017; 31(2):244-248. DOI: 10.1177/0897190017704751. View

Skov B, Hogdall E, Clementsen P, Krasnik M, Larsen K, Sorensen J . The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. APMIS. 2014; 123(2):108-15. DOI: 10.1111/apm.12328. View

Baldi L, Mengoli M, Bisagni A, Banzi M, Boni C, Rossi G . Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells. Lung Cancer. 2014; 86(2):291-5. DOI: 10.1016/j.lungcan.2014.09.011. View

10.

Kuo Y, Wu S, Ho C, Shih J . Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol. 2010; 5(12):2039-40. DOI: 10.1097/JTO.0b013e3181f43274. View

11.

Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W . A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011; 71(18):6051-60. PMC: 3278914. DOI: 10.1158/0008-5472.CAN-11-1340. View

12.

Lou N, Zhang X, Chen H, Zhou Q, Yan L, Xie Z . Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. Oncotarget. 2016; 7(40):65185-65195. PMC: 5323147. DOI: 10.18632/oncotarget.11218. View

13.

Brega E, Brandao G . Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective. Front Oncol. 2014; 4:182. PMC: 4099940. DOI: 10.3389/fonc.2014.00182. View

14.

Santelmo C, Ravaioli A, Barzotti E, Papi M, Poggi B, Drudi F . Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib. Lung Cancer. 2013; 81(2):294-6. DOI: 10.1016/j.lungcan.2013.04.009. View

15.

Sweis R, Thomas S, Bank B, Fishkin P, Mooney C, Salgia R . Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. Cureus. 2016; 8(2):e513. PMC: 4807912. DOI: 10.7759/cureus.513. View

16.

Chen X, Zhang J, Hu Q, Li X, Zhou C . A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene. Lung Cancer. 2013; 81(2):308-10. DOI: 10.1016/j.lungcan.2013.05.003. View

17.

Won J, Keam B, Koh J, Cho H, Jeon Y, Kim T . Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Ann Oncol. 2014; 26(2):348-54. DOI: 10.1093/annonc/mdu530. View

18.

Gainor J, Varghese A, Ou S, Kabraji S, Awad M, Katayama R . ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013; 19(15):4273-81. PMC: 3874127. DOI: 10.1158/1078-0432.CCR-13-0318. View

19.

Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, Bozzetti C . EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer. 2010; 71(2):241-3. DOI: 10.1016/j.lungcan.2010.11.014. View

20.

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View